Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes (Q38524435)

3 September 2017

1 reference

title

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes (English)

1 reference

3 September 2017

1 reference

cardiovascular disease

1 reference

2

Ralph A DeFronzo

1 reference

3 September 2017

1

Ele Ferrannini

1 reference

3 September 2017

10 June 2015

1 reference

3 September 2017

European Heart Journal

1 reference

3 September 2017

36

1 reference

3 September 2017

2288-2296

1 reference

3 September 2017

34

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

3 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Pathophysiology of prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Preservation of β-cell function: the key to diabetes prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The stunned beta cell: a brief history

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dose-response effect of elevated plasma free fatty acid on insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The Look AHEAD Trial: A Review and Discussion Of Its Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Diabetes mellitus, fasting glucose, and risk of cause-specific death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metabolic syndrome: evaluation of pathological and therapeutic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin resistance and coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin resistance, insulin response, and obesity as indicators of metabolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia--13-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

21 January 2018

Is insulin atherogenic?

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The target of metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Sulfonylurea induced beta-cell apoptosis in cultured human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Mechanisms of beta-cell death in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Hypoglycemia, diabetes, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Mortality risk among sulfonylureas: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Impairment of myocardial protection in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulinotropic meglitinide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin resistance and the effects of thiazolidinediones on cardiac metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The effect of pioglitazone on the liver: role of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The effects of thiazolidinediones on blood pressure levels - a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therap

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The role of gut hormones in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Extrapancreatic effects of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of dapagliflozin on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Treatment of familial hypertriglyceridaemia with acarbose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin use and increased risk of mortality in type 2 diabetes: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effect of insulin on growth of cultured human arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Chronic insulin administration elevates blood pressure in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Molecular biology of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin resistance in the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

In vivo effect of insulin on intracellular calcium concentrations: relation to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relation of plaque lipid composition and morphology to the stability of human aortic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Residual macrovascular risk in 2013: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

Insulin Sensitivity, Vascular Reactivity, and Clamp-Induced Vasodilatation in Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV239

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHV239

1 reference

3 September 2017

1 reference

PubMed ID

26063450